RxDoctor Payments Data

Matthew Bickford, MD

Ophthalmology · Boiling Springs, SCNPI 1750841383

Payments from drug & device makers

$4,345in general payments, 2019–2025

Across 113 payments — averaging $38.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$947
  • Bausch & Lomb Americas Inc.$332
  • Sight Sciences, Inc.$243
  • Rxsight Inc$242
  • Mallinckrodt Hospital Products Inc.$241
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,13095%
  • Education$2165%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,345 in reported general payments places this provider in the 65th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$91,918
Medicare patients
308
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine18$11,237
Prednisolone Acetate102$4,187
ValacyclovirValacyclovir Hcl28$1,243
MoxifloxacinMoxifloxacin Hcl41$919
Acetazolamide ErAcetazolamide12$786
Brimonidine Tartrate14$626
ErythromycinErythromycin Base43$577
Latanoprost54$451
Ketorolac Tromethamine20$374
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$293
Timolol Maleate19$173
Ofloxacin16$159
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha16$157
Doxycycline Monohydrate12$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$947$11,23718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Boiling Springs

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →